Be the first to hear about our Early Access Program. Subscribe

Lase Innovation logo

LASE Innovation Receives SBIR Award to Study T Cell Function Over Time

LASE Innovation, a developer of the groundbreaking LP Cell Barcoding™ platform, announced that it has received a Direct-to-Phase II SBIR grant, valued at approximately $1.8 MM from the NIH.

Share This Post

Woburn, Mass., November 20, 2023–LASE Innovation, a developer of the groundbreaking LP Cell Barcoding™ platform, announced that it has received a Direct-to-Phase II SBIR grant, valued at approximately $1.8 MM from the NIH.   The study entitled “Time-Lapse Flow Cytometry for Kinetic Profiling of T-Cell Function” is designed to develop a novel platform leveraging the LP Cell Barcoding platform to enable multiple measurements of the same cells over time with flow cytometry.

The LP Cell Barcoding technology was invented in the lab of Dr. Seok-Hyun (Andy) Yun of Massachusetts General Hospital & Harvard Medical School and is being developed and commercialized by LASE. This technology provides researchers with the unprecedented ability to track high-dimensional data across multiple platforms at the single cell level.  The LP Cell Barcoding platform can individually barcode millions of cells, allowing them to be identified and tracked through a range of assays and platforms. These optical barcodes emit in the short-wave infrared (SWIR) spectrum and do not interfere with commonly used fluorescent dyes in the visible spectrum, making them widely useful across cellular analysis and multi-omics applications.

This novel technology promises to accelerate the understanding of complex diseases such as cancer, autoimmunity and neurodegenerative disorders leading to improved therapies.

“We are excited to receive this grant, our 2nd such Phase II SBIR award, which reflects the importance of the work being done by our team,” said Sheldon JJ. Kwok, CEO and co-founder of LASE Innovation.  “Comprehensive analysis of T cells requires interrogation at the single-cell level, especially given extensive T cell heterogeneity, including dozens of cell types that can alter their phenotype in response to pathogens, treatment, or interactions with other cells. Current methods cannot measure and track individual cells over time and at high throughput, which has limited the understanding of how different cells develop and respond to different stimuli.”

LASE seeks to revolutionize the field of flow cytometry through the development of Time-lapse flow™ cytometry applications.  LP-barcoded cells are acquired multiple times through the LASE cytometer to track their function over time, identifying novel ‘kinetic’ phenotypes and revealing previously hidden behaviors of the immune system.  The work enabled by this non-dilutive funding will lead to optimized Time-lapse flow protocols and assays that are customer-ready and complement the ongoing development work on the LP-enabled LASE Cytometer, supported through a previous SBIR award.

About Lase Innovation

LASE Innovation, founded in 2019 and based in Boston, is advancing biomedical research with their patented LP Cell Barcoding™ technology, enabling massively multiplexed barcoding of cells and the unprecedented ability to connect data across multiple single cell and omics platforms including flow cytometry, imaging and RNA-sequencing. LASE Innovation is in the late stages of development of their flagship LASE Cytometer and LP tagging technology enabling Time-lapse flow™ and Multi-pass flow™ cytometry applications that promise to revolutionize how users approach flow cytometry experiments and researchers connect their data across the myriad of platforms leading to accelerated discoveries for health and disease.

Please direct media inquiries to:

More To Explore

Subscribe and
Stay Informed

Subscribe below to learn about LASE news, stay up to date on new product developments, and more. 

Subscribe to Our Emails

Please enable JavaScript in your browser to complete this form.
Email Opt In